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Abstract
Background
Non-steroidal anti-inflammatory drugs (NSAIDs) have been associated with anti-tumori-
genic effects in different tumor entities. For glioma, research has generally focused on diclo-
fenac; however data on other NSAIDs, such as ibuprofen, is limited. Therefore, we
performed a comprehensive investigation of the cellular, molecular, and metabolic effects of
ibuprofen and diclofenac on human glioblastoma cells.
Methods
Glioma cell lines were treated with ibuprofen or diclofenac to investigate functional effects
on proliferation and cell motility. Cell cycle, extracellular lactate levels, lactate dehydroge-
nase-A (LDH-A) expression and activity, as well as inhibition of the Signal Transducer and
Activator of Transcription 3 (STAT-3) signaling pathway, were determined. Specific effects
of diclofenac and ibuprofen on STAT-3 were investigated by comparing their effects with
those of the specific STAT-3 inhibitor STATTIC.
Results
Ibuprofen treatment led to a stronger inhibition of cell growth and migration than treatment
with diclofenac. Proliferation was affected by cell cycle arrest at different checkpoints by
both agents. In addition, diclofenac, but not ibuprofen, decreased lactate levels in all con-
centrations used. Both decreased STAT-3 phosphorylation; however, diclofenac led to
decreased c-myc expression and subsequent reduction in LDH-A activity, whereas treat-
ment with ibuprofen in higher doses induced c-myc expression and less LDH-A alteration.
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Conclusions
This study indicates that both ibuprofen and diclofenac strongly inhibit glioma cells, but the
subsequent metabolic responses of both agents are distinct. We postulate that ibuprofen
may inhibit tumor cells also by COX- and lactate-independent mechanisms after long-term
treatment in physiological dosages, whereas diclofenac mainly acts by inhibition of STAT-3
signaling and downstreammodulation of glycolysis.
Introduction
Glioblastomas (GBM) are characterized as highly malignant brain tumors hallmarked by infil-
trating tumor cells, enhanced mitotic activity, and angiogenesis. Despite combined therapy
approaches, the median survival time following diagnosis is limited to 14.6 months with stan-
dard therapy [1]. Therefore, augmentative therapies are sought for these tumors.
Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and diclofenac may be
candidates for such an approach. Recent data indicate that treatment with NSAIDs reduces the
risk of various cancer types [2–7] and lessens tumor growth in established tumors [2,8,9]. Tra-
ditional NSAIDs are non-selective COX-1 and -2 inhibitors. Non-selective inhibition of COX-
2 leads to decreased prostaglandin synthesis [10] and prostaglandin E2 was associated with
tumor cell promotion [11,12]. In addition, inhibition of tumor cell proliferation [6] and induc-
tion of apoptosis by NSAID treatment [13,14] has also been described to occur via COX-inde-
pendent mechanisms.
We have previously shown that diclofenac, which preferentially inhibits COX-2 [15,16],
caused c-myc inhibition followed by decreased gene expression of glucose transporter 1
(GLUT-1), as well as decreased LDH-A, and lactate secretion [17]. In addition, previous work
in our lab demonstrated that diclofenac inhibits STAT-3 phosphorylation and lactate forma-
tion, induces cell cycle arrest at G2/M, and delays tumor growth in an in vivo animal model
[18]. Diclofenac also influences the mitochondrial adenine nucleotide transferase as well as the
OXPHOS complex V (F0F1-ATPase). This leads to decoupling of oxidative phosphorylation,
which reduces ATP generation and thus cell proliferation [16]. In neuroblastoma, diclofenac
enhanced chemotherapy induced apoptosis by augmentation of p53 [19]. It has also been
determined that diclofenac treatment of neuroblastoma xenografts significantly reduced tumor
growth in nude rats [8].
GBM are able to metabolically switch from the oxidative to the glycolytic pathway, a charac-
teristic of these highly proliferative tumors [20]. Glucose is transported into the cell by glucose
transporters to allow cytosolic glycolysis [21]. LDH-A catalyzes the conversion of pyruvate
into lactate [22], which is then exported out of the cell by monocarboxylate transporters
(MCT) [23]. High glycolytic activity is accompanied by increased extracellular lactate levels
that are associated with poorer patient survival in cases of malignant glioma [24]. Glycolysis
can be stimulated by oncogenes such as c-myc [25], and c-myc itself is a direct target of the
master regulator STAT-3 [26].
Oxidative phosphorylation may serve as an alternative energetic pathway in tumor cells, but
diclofenac has also been shown to inhibit OXPHOS [16]. Diclofenac may, therefore, efficiently
inhibit several key steps of tumor metabolism.
Published results for the effects of ibuprofen on tumor cells are sparse, although ibuprofen
is an equipotent COX-1 and COX-2 inhibitor [16,27] [28–30]. For glioma, documented effects
have been published [9,31], although patients in these studies frequently used ibuprofen as
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pain reliever [32]. It was, therefore, of interest to also investigate the action of ibuprofen on gli-
oma cells and to compare functional as well as metabolic effects of this NSAID to the well-
described effects of diclofenac. In other tumor models, ibuprofen was shown to bind and acti-
vate the peroxisome proliferator-activated receptor γ (PPARγ) as observed from reporter gene
assays [28]. It has been suggested that increased PPARγ suppresses cell proliferation of various
tumor entities [29]. Additionally, ibuprofen (1–3 mM) is able to inhibit nuclear factor κ-light-
chain-enhancer of activated B cells (NF-κB) activation by preventing the degradation of IκBα,
the NF-κB inhibitory protein, in prostate cancer [30].
The NSAID diclofenac has been widely investigated and several of its effects are attractive
for the treatment of tumors. In contrast, ibuprofen lacks investigation for its impact and effec-
tiveness in glioma, and its molecular mechanisms of action are by-far less understood. Signifi-
cant effects of ibuprofen on proliferation and migration in human cells could suggest the
substance as adjuvant therapy with positive effects on glioma treatment. Therefore, the current
study was designed to evaluate the anti-tumorigenic effects of ibuprofen in comparison to
diclofenac. This analysis was conducted in concentrations of NSAIDs achievable in patients,
and the effects of these compounds on proliferation, migration, and lactate formation of differ-
ent human glioma cells are presented.
Materials and Methods
Ethics statement
The ethics board of the University of Regensburg, Germany, has approved the use of human
material for this study (No° 11-103-0182). All patients provided written informed consent to
participate in this study.
Tumor cell lines
Human high-grade glioma cell lines U87MG and A172 were obtained from American Type
Culture Collection (Manassas, USA). HTZ-349 is a primary tumor cell culture derived from
resection of a human glioblastoma as previously described [33]. Tumor cells were maintained
as monolayer cultures in Dulbecco’s Modified Eagles Medium (DMEM with 1g/L glucose;
Sigma-Aldrich, Germany), supplemented with 10% fetal calf serum (FCS; Biochrom, Ger-
many) at 37°C, 5% CO2, 95% humidity in a standard tissue culture incubator. For all functional
assays, cells were starved by FCS deprivation (lactate measurements) or reduction to 5%
(migration, proliferation, Western blot) 24 h prior experiments.
Chemicals and drugs
Aspirin (ASA), ibuprofen-sodium, and diclofenac-sodium were purchased from Sigma-
Aldrich, Germany. ASA and ibuprofen-sodium were dissolved in 1x PBS, and Diclofenac-
sodium in DMSO. STATTIC was purchased from EMDMillipore, Germany. NaOxamat was
purchased from Fluka, Germany and dissolved in media. Chemicals and drugs were further
dissolved to final concentrations in media as shown in detail in the results and figure sections.
Enzymatic determination of lactate in tumor cell supernatants
Lactate levels in cell culture supernatants were measured by means of a Cobas analyzer (Roche,
Germany) using reagents from Roche (Germany) at the clinical laboratory of the Department
of Neurology, University of Regensburg, Germany.
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LDH activity measurement
To control for LDH enzyme activity, the LDH-cytotoxicity assay (Promega, Mannheim, Ger-
many) was used. The assay utilizes an enzymatic coupling reaction: LDH oxidizes lactate to
generate NADH, which then reacts with pyruvate and a dye to generate yellow color. LDH
activity was quantified with a plate reader (VarioSkan Flash Multimode Reader, Thermo Scien-
tific, USA) at 490 nm absorption. Briefly, cells were seeded 24 h prior to treatment with 5 x103
cells/well in serum free media and incubated with either the indicated concentrations of diclo-
fenac (0.05–0.3 mM), ibuprofen (0.5–5 mM), or STATTIC (5–20 μM), NaOxamat (25 mM)
was used as a positive control. 24 h later, LDH activity was measured.
Determination of IC50 and cell proliferation
For determination of IC50 and cell proliferation, 2 x10
4 cells of each cell line were incubated
with either the indicated concentrations of diclofenac (0.05–0.2 mM), ibuprofen (0.5–2 mM),
or ASA (0.05–0.2 mM) and corresponding controls before OD determination by crystal violet.
Briefly, medium was exchanged with 0.5% crystal violet in 20% methanol solution and cells
were stained for 10 min. After washing and drying, the crystal violet was diluted into a homog-
enous solution by addition of 0.1 M sodium citrate in 50% ethanol, and measured at 550 nm
(VarioSkan Flash Multimode Reader, Thermo Scientific, USA). To determine IC50 concentra-
tions, cells were treated for 24 h and proliferation analyzed at 0 and 96 h. Additionally, prolifer-
ation rates were determined at 0, 24, 48, 72, 96, and 120 h after onset of treatment.
Proliferation rates with STATTIC (at concentrations of 5, 10, 20 μM) treatment were deter-
mined by use of the CyQuant Direct Cell Proliferation Assay according to the manufacturer’s
protocol, higher STATTIC concentrations caused cell detachment. Additionally, the CyQuant
assay served as a verification for the crystal violet assay. Briefly, cells were seeded and treated as
described before. OD was measured at 0, 48, 96 and 144 h at 535 nm. For all assays, back-
ground fluorescence was subtracted and values were normalized to 0 h. Assays were performed
in triplicates and repeated twice.
Determination of cell migration
Tumor spheroids were generated by seeding 5 x 103 cells onto agarose-coated wells (1% agarose
in 1x PBS). Cells were cultured for 24 h to allow spheroid formation. Mature spheroids were
transferred into non-coated 96-well plates containing the corresponding drug (diclofenac: 0.05,
0.1, 0.2 mM, ibuprofen: 0.5, 1, 2 mM, STATTIC: 5, 10, 15 μM). Cell migration was monitored
at 0, 6, 24 and 30 h, taking into account the earliest time point when migration was measurable
to prevent dilution of results by proliferation effects. The area covered by cells migrating away
from the spheroid was photographed at indicated time points, and its greatest diameter was
measured manually (ImageJ software, NIH, USA) by a investigator. Assays were performed in
triplicates and repeated three times.
Attachment assay
1.5 x 105 HTZ-349 cells were seeded in 6-well plates and incubated for 24 h prior to treatment
with 0.05 mM diclofenac or ibuprofen (0.1, 2 mM) alongside with the corresponding controls.
After 24 h of treatment, attachment assays were performed with pre-treated cells as described
earlier [34]. Briefly, 1.5 x 104 cells were seeded in 96-well plates with treatment media. After 5,
15, 30, 60, and 120 min, wells were washed once with 1x PBS and attached cells were incubated
for 6 h prior to quantification via CyQuant assay.
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Cell cycle analysis
For flow cytometric measurements of cellular DNA content, cells were fixed with ice-cold 70%
methanol. After washing with PBS, cells were treated with 100 μg/ml RNase A (Invitrogen,
Germany) for 20 min at 37°C. Subsequently, cells were stained with 50 μg/ml propidium iodide
(Sigma-Aldrich, Germany) and analyzed with a FACS Canto™ (Becton Dickinson, Germany).
Histograms were created using ModFit LT™ software (Verity Software House, Topsham, USA).
At all times loss of cells was prevented by collecting also detached cells from the cell culture
supernatant.
Quantitative real-time PCR
For RNA isolation 1 x 105 cells were seeded in 6-well plates, incubated for 24 h prior to treat-
ment with 2 mM ibuprofen, 0.2 mM diclofenac, or 0.2 mM ASA and corresponding controls
for 24 h. Total RNA was isolated by use of the Nucleo Spin RNA Plus Kit (Macherey-Nagel,
Germany) according to the manufacturer’s instructions. Reverse transcription was performed
with the Reverse Transcription System (Promega, Germany) according to the manufacturer’s
protocol. Quantitative RT-PCR were performed as previously described [35].
Western blot
To evaluate (phosphorylated) protein expression of LDH-A, STAT-3/pSTAT-3, and c-myc,
whole cell lysates were prepared with RIPA-buffer and samples (40 μg) were subjected to West-
ern blotting (10% SDS-PAGE). Membranes were sequentially analyzed with antibodies to
GAPDH2 (Santa Cruz Biotechnology, Heidelberg, Germany), c-myc, LDH-A, STAT-3, phos-
phorylated STAT-3 (pSTAT-3) (all Cell Signaling, New England Biolabs GmbH, Germany),
and β-actin (Sigma-Aldrich, Germany) in dry milk (1%). Expression was measured by chemo-
luminescence (ECLWestern Blot Bright, Biozym, Germany). Intensities of protein bands were
measured with ImageJ software and protein regulation of 3 Western blots each (n = 3) was cal-
culated by normalization to loading and treatment control using GraphPad Prism software
(version 6, GraphPad Software, USA).
Statistical analysis
Analyses of significant differences between treatment groups were performed by one- (lactate
levels, LDH activity) or two-way ANOVA and in case of FACS analysis by Student´s t-test.
Post-hoc tests were performed with p values< 0.05. Data were analyzed by GraphPad Prism
software (version 6, GraphPad Software, USA). Confidence intervals (CI) were around 95%.
Results
The half maximal inhibitory concentrations (IC50) were similar for all
glioma lines
First, non-toxic NSAID concentrations for further treatment of human malignant glioma cells
were determined by culturing the human glioma cell lines HTZ-349, U87MG, and A172 in
absence or presence of increasing concentrations of ibuprofen (0.5–2.0 mM; Fig 1A), diclofenac
(0.05–0.2 mM; Fig 1B) or ASA (0.05–0.2 mM; Fig 1C) for 96 h. IC50 values were 1 mM for ibu-
profen and 0.1 mM for diclofenac. ASA treatment had no significant effect on proliferation of
HTZ-349, U87MG, or A172 glioma cells. The different IC50 of each substance did not vary sub-
stantially between the cell lines. For further experiments, we used concentrations ranging
between 0.5 and 2 mM for ibuprofen and between 0.05 and 0.2 mM for diclofenac. ASA was
Ibuprofen and Diclofenac Inhibit Human Glioma
PLOSONE | DOI:10.1371/journal.pone.0140613 October 20, 2015 5 / 23
used at the same concentrations as diclofenac, since both drugs are administered to patients at
comparable concentrations when used on a long-term basis (e.g. secondary prevention of myo-
cardial infarction and stroke).
Ibuprofen and diclofenac decreased proliferation of glioma cells
Proliferation inhibiting effects of the two NSAIDs, ibuprofen and diclofenac, on human glioma
cell lines were analyzed in long-term assays (HTZ-349: Fig 2; A172, U87MG: S1 Fig). Daily
crystal violet staining showed significantly impaired proliferation dependent on increasing dos-
ages of ibuprofen (Fig 2A) and diclofenac (Fig 2C). Starting at 72 h, all dosages resulted in sig-
nificant anti-proliferative effects (p 0.0001). Correspondingly, CyQuant measurements (B:
ibuprofen, D: diclofenac) confirmed the crystal violet assays. Both NSAIDs had similar impact
Fig 1. IC50 is distinct for diclofenac, ibuprofen, and ASA.Concentration-dependent cytotoxicity was investigated by treating the glioma cell lines HTZ-
349, U87MG, and A172 in absence or presence of increasing concentrations of (A) ibuprofen (0.5–2.0 mM), (B) diclofenac (0.05–0.2 mM), or (C) ASA (0.05–
0.2 mM) and DMSO as control in corresponding concentrations. The assays showed a significant linear concentration-dependent decrease of cell viability,
which significantly differed between (A) ibuprofen (IC50, 1 mM) and (B) diclofenac (IC50, 0.1 mM). In contrast, (C) ASA had no significant effect on cell
proliferation with given concentrations. Statistics: 95% CI, *** = 0.001 < p 0.0001, **** = p 0.0001.
doi:10.1371/journal.pone.0140613.g001
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Fig 2. Ibuprofen and diclofenac decrease proliferation. Proliferation was analyzed using crystal violet staining and results were verified via the CyQuant
Direct Cell Proliferation assay in HTZ-349. (A) Starting at 72 h, all ibuprofen concentrations (0.5, 1, 2 mM) resulted in significant reduction of HTZ-349
proliferation (compared to non-treated Ctrl, 95% CI, p < 0.05). 2 mM ibuprofen caused significant proliferation inhibition at 24 h (0.01 > p 0.001) and 48 h
(p < 0.0001). (B) Proliferation decrease was verified in CyQuant measurements. Additionally, physiological ibuprofen concentrations (0.05–0.3 mM) were
analyzed. Most demonstrated significant proliferation decrease after long-term treatment (144 h) compared to the non-treated controls (0.3–2
mM = p < 0.0001, 0.1 mM = 0.01 > p 0.001; 95% CI). (C) Similar proliferation reducing effects were obtained with diclofenac at respective concentrations
(0.05, 0.1, 0.2 mM) (compared to DMSO control, 95%CI, p < 0.05). The highest concentration of 0.2 mM reached significant proliferation inhibition at 24 and
48 h compared to control (p < 0.0001). (D) CyQuant assay measurements of HTZ-349 treated with diclofenac were broadly in compliance with previously
obtained results by crystal violet staining. (E) In contrast, ASA exhibited neither concentration- nor time-dependent effects, and only unspecific effects were
observed at 96 h (0.05 mM: 0.05 > p 0.01) and 120 h (0.2 mM: p < 0.0001). (F) Corresponding CyQuant assay measurements of HTZ-349 treated with ASA
verified the results. Treatment of A172 and U87MG cells showed similar results (see S1 Fig).
doi:10.1371/journal.pone.0140613.g002
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on proliferation of A172 (Figs A, C and E in S1 Fig) and U87MG (Figs B, D and F in S1 Fig).
However, both NSAIDs were more effective on HTZ-349 and A172 than U87MG. Additional
ibuprofen treatment (0.05, 0.1, 0.3 mM) using patient-relevant plasma concentrations of ibu-
profen (0.1, 0.3 mM; FDA information: http://www.drugs.com/pro/ibuprofen.html) revealed
that, on long-term exposure, (144 h) low ibuprofen concentrations of 0.1 mM were efficient
to cause a significant proliferation decrease in HTZ-349. Proliferation remained generally unaf-
fected by ASA (HTZ-349: Figs E and F in Fig 2, A172: S1E Fig). Only U87MG responded with
a decrease after 120 h (S1F Fig). Thus, ASA was used as control, but not further investigated
for tumor cell inhibiting capacities.
Ibuprofen led to G1/G0 cell cycle arrest whereas diclofenac caused an
arrest at G2/M
Cell cycle analyses were performed to distinguish the individual effects of ibuprofen or diclofe-
nac treatment on glioma cell proliferation and to confirm the observed effects were not caused
by toxicity of either NSAID (Fig 3). Human glioma cell lines HTZ-349 (Fig 3A), A172 (Fig 3B),
and U87MG (Fig 3C) were cultured in the presence of increasing concentrations of ibuprofen
(1, 2 mM) or diclofenac (0.1, 0.2 mM) as well as corresponding controls. After 48 h, all cells
were harvested for cell cycle analysis by flow cytometry.
Ibuprofen treatment resulted in a concentration-dependent accumulation of cells in G1/G0
phase in all cell lines (HTZ349: 1 mM ibuprofen: p = 0.001; 2 mM ibuprofen: p = 0,0001; A172:
1 mM ibuprofen: p = 3.8 x 10−6; 2 mM ibuprofen: p = 6.9 x 10−7; U87MG: 1 mM ibuprofen:
p = 4.7 x 10−5; 2 mM ibuprofen: p = 0.0006) concomitant with a decrease of cells in S-phase
(HTZ349: 1 mM ibuprofen: p = 0.0007; 2 mM ibuprofen: p = 1.2 x 10−6; A172: 1 mM ibupro-
fen: p = 0.0002; 2 mM ibuprofen: p = 0.0006; U87MG: 1 mM ibuprofen: p = 8.9 x 10−5; 2 mM
ibuprofen: p = 0.0002), indicating impaired proliferation.
In contrast, diclofenac had different effects on each cell line. The amount of cells in S-phase
was decreased in A172 and U87MG (A172: 0.1 mM diclofenac: p = 0.21; 0.2 mM diclofenac:
p = 0.0001; U87MG: 0.1 mM diclofenac: p = 0.03; 0.2 mM diclofenac: p = 0.002). However,
HTZ-349 cells accumulated in S- and G2/M-phase with increasing concentrations (HTZ349:
0.1 mM diclofenac: p = 0.009; 0.2 mM diclofenac: p = 0.002). Here, cell cycle arrest was accom-
panied by the appearance of a sub-G1 peak along with cellular debris, indicating cellular disin-
tegration and possibly cytotoxic effects (S2A Fig). This was not observed with ibuprofen
treatment or diclofenac in the other cell lines. However, whereas HTZ-349 and U87MG cells
accumulated in G2/M and S-phase, A172 cells arrested in G1/G0 similar to ibuprofen condi-
tions. Physiological ibuprofen concentrations had long-term inhibiting effects on proliferation
(Fig 2B) and caused cell cycle alterations already after 48 h (Fig 3D). Dose-dependent accumu-
lation of cells in G1 was observed for ibuprofen (0.3 mM: p = 4.2 x 10−6; 0.5 mM: p = 1.2 x
10−5; 1 mM: p = 3.3 x 10−8; 2 mM: p = 7.1 x 10−5). A concomitant shift of cells from the S-
phase (0.3 mM: p = 0.01; 0.5 mM: p = 0.003; 1 mM: p = 9.7 x 10−7; 2 mM: p = 8.7 x 10−6)
resulted in decreased proliferation. Detailed FACS analysis plots for every condition and cell
line are shown in the supplements (HTZ-349: Figs A and D in S2 Fig, A172: S2B Fig, U87MG:
S2C Fig).
Ibuprofen and diclofenac decreased migration of glioma cell lines
Glioma pathogenesis is characterized by rapid tumor cell migration. Former results [35] have
shown that lactate influences migration of human glioma cell lines. Here, influence on glioma
cell migration was investigated by spheroid migration assays (Fig 4). Spheroids of glioma cells
were transferred, to be cultured in presence of increasing ibuprofen (0.5 to 2 mM) or diclofenac
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(0.05 to 0.2 mM) concentrations, and cells were given time to migrate from the spheroid (Fig
4C) for up to 30 h. Strong inhibitory effects on migration were obtained with all ibuprofen con-
centrations in HTZ-349 (Fig 4A and S3A Fig). Starting 24 h after treatment, concentration-
and time-dependent migration-inhibiting effects were observed. The same applied to A172
(S3B Fig) and U87MG (S3C Fig), which responded significantly to ibuprofen starting 6 h after
treatment. Additionally, all diclofenac concentrations significantly decreased migration start-
ing at 24 h in a dose-dependent manner (Fig 4B and S3D Fig). Similar results were obtained for
A172 with diclofenac (S3E Fig), whereas U87MG were—in contrast to ibuprofen treatment
(S3C Fig)—resistant to diclofenac until 30 h of treatment (S3F Fig).
Ibuprofen proved to be significantly more effective to reduce the migratory capacity in all
glioma cells (Fig 4D). 30 h after exposure to 2 mM ibuprofen, spheroid diameters were only
45% of the control size, whereas in the corresponding dicofenac treated (0.2 mM) spheroids
Fig 3. Ibuprofen and diclofenac led to cell cycle arrest at different checkpoints.Human glioma cell lines HTZ-349 (A), A172 (B), and U87MG (C) were
cultured in the presence of increasing concentrations of diclofenac (0.1, 0.2 mM) or ibuprofen (1, 2 mM) and respective DMSO controls. Cells were harvested
for cell cycle analysis after 48 h of incubation. Proliferation was significantly reduced as measured by a reduced number of cells in S-phase in all conditions
except 0.1 mM diclofenac in A172 as well as 0.1 and 0.2 mM diclofenac in HTZ-349. With diclofenac treatment, HTZ-349 and U87MG cells showed an
accumulation of cells in the G2/M (U87MG) and S-phase (HTZ-349), whereas A172 arrested in the G1 phase. Ibuprofen generated accumulation of cells in
the G1 phase in all cell lines. Additional treatment with 0.05–2 mM ibuprofen (D) confirmed dose-dependent accumulation of HTZ-349 in G1 accompanied by
a decrease of cells in S- and G2/M-phase. Bar graphs showmean values of three independent experiments. Histograms are depicted in the supplements (S2
Fig) and show representative plots of each treatment condition.
doi:10.1371/journal.pone.0140613.g003
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diameters were 68% of the control. The most prominent effects were achieved in U87MG cells,
where ibuprofen treatment resulted in a spheroid diameter decrease of 40%, whereas diclofenac
inhibited spheroid migration only by 11% (S3C and S3F Fig).
The spheroid assay is not designed to exclude confounding effects that may arise from
impaired proliferation. However, the observed reduction of migratory capacity is likely inde-
pendent, since significant reduction of proliferation was measurable only from 48 h on, as
shown above (Fig 2 and S1 Fig).
Investigation of mechanisms underlying reduced migratory capacity revealed decreased
attachment of HTZ-349 cells treated with low dosages of either ibuprofen (Fig 4E) or
Fig 4. Ibuprofen and diclofenac decrease migration. Spheroids of human glioma cell line HTZ-349 (5 x
103 cells/well) were cultured in presence of increasing (A) ibuprofen (0.5–2 mM) or (B) diclofenac
concentrations (0.05–0.2mM) and monitored for 30 h. During this time, pictures of cells migrating from the
spheroids were taken periodically to monitor migratory capacity at treatment conditions (C) (scale
bar = 500 μm). Migration was significantly inhibited by ibuprofen (A) in a time- and concentration-dependent
manner. After 24 h, all concentrations demonstrated significantly greater migration over controls (95%CI,
**** = p < 0.0001). (D) A high concentration of ibuprofen, 2 mM, resulted in significant migration inhibition
noticeable by 6 h (S3A Fig). Diclofenac resulted in similar (B), although less pronounced (D), effects.
Measurement of attachment capacities after 0.1 mM ibuprofen (E) or 0.05 mM diclofenac (F) revealed
adhesion deficits of HTZ-349 cells compared to controls within the first 30 minutes (95%CI, * =
0.05 > p 0.01, ** = 0.01 > p 0.001, *** = 0.001 > p 0.0001, **** = p < 0.0001.).
doi:10.1371/journal.pone.0140613.g004
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diclofenac (Fig 4F) until 30 minutes after seeding. To gain deeper insight into whether the cyto-
skeleton may be affected by NSAID treatment, resulting in the observed migration deficits, we
performed phalloidin staining of actin filaments (S4 Fig). Significantly larger cells with
enhanced spreading were observed with higher dosages of diclofenac (Figs A and B in S4 Fig)
or ibuprofen (Figs C and D in S4 Fig). We assumed an increase of filamentous actin (F-actin)
was responsible for migration deficits and attachment delay. However, measurement of F-actin
and G-actin (globular actin) ratios revealed neither significant increase nor decrease of F-actin
levels (Figs E, F and G in S4 Fig).
Ibuprofen and diclofenac inhibited LDH activity and reduced lactate
production
Recently, our group demonstrated that diclofenac treatment causes decreases of lactate produc-
tion in the mouse glioma cell line GL261 [18]. It was, therefore, investigated whether ibuprofen
had a similar effect on lactate concentration and LDH activity. To investigate this, all cell lines
were treated with ibuprofen (0.5, 1.0, and 2.0 mM) and diclofenac (0.05, 0.1, and 0.15 mM)
(Fig 5). Supernatants were analyzed for extracellular lactate concentrations after 24 h when
proliferation was not yet altered by the treatment (Fig 2 and S1 Fig). With ibuprofen, lactate
production was significantly reduced only with the highest concentration of 2 mM ibuprofen
in HTZ-349 and U87MG glioma cells (Fig 5A and 5C) (p< 0.05). In A172, ibuprofen did not
substantially reduce extracellular lactate levels in low or in high concentrations (Fig 5B). Diclo-
fenac significantly reduced lactate levels in a dose-dependent manner in all cell lines and the
effects were stronger than those observed with ibuprofen (Figs A–C in Fig 5). Along with
decreased lactate levels, LDH activity was inhibited after treatment with 0.1 or 0.2 mM diclofe-
nac as well as with 2 mM ibuprofen (Fig 5D). Sodium oxamate, a competitive inhibitor of
LDH, was used as a positive control.
Ibuprofen and diclofenac decreased STAT-3 phosphorylation, but
modulated c-myc differently
Many highly proliferative solid tumors are characterized by intrinsic or induced expression of
transcription factors which affect the cell cycle. High expression and activation of STAT-3 and
overexpression of its downstream target c-myc are well known to be pathophysiological mech-
anisms in malignant glioma [36]. As diclofenac impacts LDH-A, which is targeted directly by
c-myc [37], STAT-3 and c-myc were investigated as possible modulators of the observed func-
tional effects. Protein expression levels and phosphorylation of c-myc, pSTAT-3, STAT-3, and
LDH-A in HTZ-349 (Fig 6A and S5 Fig), A172 (Figs A and B in S6 Fig), and U87MG (Figs A
and B in S7 Fig) were determined after 24 h exposure to increasing ibuprofen or diclofenac
concentrations. As shown in Fig 6A, increasing concentrations of both ibuprofen and diclofe-
nac led to a reduction of STAT-3 phosphorylation without affecting total STAT-3 expression
in HTZ-349, this was also observed in A172 (S6 Fig) and U87MG (S7 Fig). Against expectation,
c-myc expression was enhanced significantly after treatment with ibuprofen, whereas diclofe-
nac reduced c-myc. Quantifications by Western blot replicate assays revealed these effects to be
consistent (see S5, S6B and S7B Figs). However, it has to be noted that changes of pSTAT-3
and c-myc expression were significant only with high ibuprofen treatment (2 mM) and
remained unchanged at physiological concentrations (Figs C and D in S5 Fig). This inducing
effect of ibuprofen was consistently observed in all cell lines (Fig 6A, S5A Fig; Figs A and B in
S6 and S7A Figs), whereas diclofenac acted contrarily in HTZ-349 and A172 (Fig 6A, S5B Fig;
Figs A and B in S6 Fig). Combined with the decrease of STAT-3 phosphorylation, LDH-A
revealed a trend towards lower expression at higher concentrations of both agents. As LDH-A
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persists with a long protein half-life [38], mRNA expression was assessed via qRT-PCR after
24 h exposure of the cells either to ibuprofen, diclofenac, or ASA. For HTZ-349 (Fig 6B) and
U87MG (Figs B and C in S7 Fig), a significant decrease of LDH-A was confirmed after expo-
sure to diclofenac, and for A172, a consistent downward trend was detected (S6C Fig). In con-
trast, LDH-A expression was not decreased in either HTZ-349 (Fig 6B and S5 Fig) or in
U87MG (S7 Fig) cells following ibuprofen treatment, while down-regulation was significant in
A172 cells (S6C Fig).
Fig 5. Ibuprofen and diclofenac decrease lactate levels and LDH activity. Human glioma cell lines HTZ-349, A172, and U87MG (105 cells/well) were
cultured for 24 h with increasing concentrations of ibuprofen or diclofenac as indicated, then supernatants were harvested for lactate level measurement (A–
C). Measurements were normalized to cell number. Diclofenac treatment resulted in a significant decrease of lactate at all concentrations and in all cell lines.
In contrast, ibuprofen cause a reduction of lactate accumulation only at concentrations of 2 mM in HTZ-349 and U87MG. These observations are reflected by
LDH activity measurements (D) which exhibited decreased activity with increasing concentrations of diclofenac. LDH activity reduction with ibuprofen
treatment occurred only at a concentration of 2 mM. Statistics: 95%CI, * = 0.05 > p 0.01, ** = 0.01 > p 0.001, *** = 0.001 > p 0.0001, **** =
p < 0.0001.
doi:10.1371/journal.pone.0140613.g005
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Restricting phosphorylation of STAT-3 led to a decrease of c-myc and
LDH-A as well as reduced proliferation and migration
To substantiate a direct effect of ibuprofen and diclofenac on STAT-3 phosphorylation, the
specific STAT-3 inhibitor STATTIC was used. STATTIC restricts the phosphorylation of
STAT-3 at the physiologically relevant tyrosine residue 705 (Y705) [39]. Treatment signifi-
cantly decreased STAT-3 phosphorylation in a concentration-dependent manner, along with
reduction of the downstream target c-myc (HTZ-349: Fig 7A and S8A Fig; A172: S9A Fig;
U87MG: S10A Fig). STATTIC exerts a specific effect on Y705 and total STAT-3 and STAT-3
phosphorylated at the serine residue 727 (S727) remained constant after 24 h treatment.
LDH-A expression was not affected, except in U87MG cells which exhibited a significant
decrease in LDH-A at 20 μM STATTIC compared to DMSO Ctrl (0.05< p 0.01). LDH-A
activity was reduced significantly after 24 h of treatment in these cells (p< 0.0001), suggesting
a functional effect. Additionally, qRT-PCR revealed a strong decrease of LDH-A mRNA
expression 24 h after treatment with 20 μM STATTIC (S8B Fig). In human glioma cells
exposed to STATTIC, migration (HTZ-349: Fig 7B; A172: S9B Fig; U87MG: S10B Fig) and
proliferation (HTZ-349: Fig 7C; A172: S9C Fig; U87MG: S10C Fig) decreased considerably,
depending on increasing concentrations. STATTIC was observed to decrease migration simi-
larly to ibuprofen in HTZ-349 (Fig 4D and S8C Fig), A172 (S3B and S9B Figs), and U87MG
cells (S3C and S10B Figs).
Discussion
In this study, the effects of ibuprofen and diclofenac on proliferation, migration and lactate for-
mation of human HTZ-349, U87MG and A172 glioma cell lines were investigated. In addition,
Fig 6. Ibuprofen and diclofenac affect STAT-3 signalling differentially. Transcription factors within the STAT-3 signalling pathway were investigated by
Western blot (40 μg of protein) after incubation with increasing ibuprofen (0.5, 1, 2 mM) or diclofenac concentrations (0.05, 0.1, 0.2 mM) for 24 h. (A)
Ibuprofen and diclofenac reduced STAT-3 phosphorylation in HTZ-349 cells without affecting total STAT-3 levels (for detailed quantification see S5 Fig). The
STAT-3 downstream target c-myc was significantly upregulated by ibuprofen (S5A Fig), whereas diclofenac blocked pSTAT-3 and c-myc in a concentration-
dependent manner (S5B Fig). LDH-A, a direct target of c-myc, showed negative trends, but not to significant extent. Corresponding quantitative RT-PCR
revealed significant LDH-A transcript decrease with diclofenac (0.2 mM, compared to control and DMSO control, 95% CI, * = 0.05 > p 0.01). Ibuprofen (2
mM) had no impact on LDH-A expression (B). Similar observations were made with ASA (0.2 mM). Corresponding results for A172 and U87MGwere
generated (see S6 and S7 Figs).
doi:10.1371/journal.pone.0140613.g006
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the functional consequences and molecular mechanisms of these effects were explored. Our
data provide evidence that long-term treatment with ibuprofen reduces human glioma cell pro-
liferation and migration ability more effectively than diclofenac. Our results indicate that both
Fig 7. Inhibition of STAT-3 phosphorylation modulates signalling along with functional effects. STAT-3 phosphorylation at Y705 is inhibited by
STATTIC. HTZ-349 cells were exposed to increasing STATTIC concentrations (5, 10, 15/20 μM) for 24 h. (A) pSTAT-3, c-myc, and LDH-A expression were
investigated byWestern blot (40 μg of protein). A decrease in both phosphorylation of pSTAT-3 and expression of its downstream targets, c-myc and LDH-A,
was observed. Total STAT-3 and STAT-3 phosphorylated at the S727 residue remained unchanged (for quantification see S8A Fig). Migration (B) and
proliferation (C) showed a significant concentration-dependent inhibition (95%CI, **** = p < 0.0001) with increasing doses of STATTIC. Migration was
inhibited significantly from 24 h on with all concentrations (B), whereas proliferation was reduced significantly with 20 μM starting at 48 h (C). LDH-A activity
was reduced in a concentration-dependent way, with significance when cells were exposed to 20 μM of STATTIC (D) (95%CI, **** = p < 0.0001).
doi:10.1371/journal.pone.0140613.g007
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agents are significantly more effective than ASA, which caused no significant changes to
human glioma cells in any assay investigated here. Since anti-tumorigenic effects of ASA are
discussed in the literature [16], the missing effect here is probably due to the fact that ASA was
intentionally used at concentrations normally for long term administration to patients rather
than acute treatment. Diclofenac was applied in physiological concentrations which corre-
spond to serum levels of approved therapeutic use in humans (FDA information for diclofenac:
http://www.drugs.com/pro/diclofenac.html). In contrast, we observed most significant effects
of ibuprofen in our in vitro assays with concentrations exceeding the appropriate physiological
concentrations (FDA information for ibuprofen: http://www.drugs.com/pro/ibuprofen.html).
Long-term treatment in routinely recommended concentrations has promising inhibitory
effects on cell cycle and cell proliferation, in addition, higher ibuprofen concentrations may be
reached in regions of blood-brain-barrier disruption which can accompany glioma [40].
A dose-dependent highly-significant restriction of cell migration and proliferation by ibu-
profen, and to a lesser extent, diclofenac, was observed. Ibuprofen was determined to be a
strong and potent inhibitor of the cell cycle at the G1/G0 state in all cell lines tested, whereas
diclofenac arrested them mainly at the G2/M check-point and in S-phase. This corresponds
well to published literature, where a G1/G0 arrest by ibuprofen has been shown in colon [41]
and prostate cancer cells [42]. In contrast, diclofenac treatment led to an accumulation of cells
in S- and G2/M phase. This is in line with our previous results regarding glioma cells [18] as
well as data from other tumor entities [43]. The sub-G1 peak observed in HTZ-349 probably
also indicates cytotoxic effects, even though a contribution of apoptotic cell death cannot be
fully excluded. However, this effect was not observed in any other cell line. More insight into
the differential sensitivities of glioma cells towards NSAIDs regarding cell cycle arrest could
further elucidate their tumor inhibiting abilities.
To explain the data obtained in this work, we hypothesized a potential COX-independent
mechanism for the non-selective COX inhibitor ibuprofen [27], as ASA, a preferential COX-1
inhibitor [27], exhibited no effects, and ibuprofen non-selectively induced more significant
effects than diclofenac, a slightly preferential COX-2 inhibitor [15]. Missing effects of ASA are
likely due to our use of concentrations administered to patients on a long-term basis and corre-
spond to a controversial debate within published literature [16], where often only dosages of
acute treatment are successful. Both COX-dependent [44] and -independent mechanisms for
anti-tumorigenic action of NSAIDs have been reported, and merging studies stress other
modes of action for NSAIDs besides COX-inhibition. Results of rat model experiments suggest
that NSAIDs, including ibuprofen, may prevent colon carcinogenesis via induction of enzymes
which detoxify potential carcinogens [45]. In addition, diclofenac induces apoptosis partly by
prevention of tumor necrosis factor α (TNF-α) induced nuclear translocation of NF-κB [46].
However, TNF-α signalling is not the main contributor to apoptosis induction, supporting a
synergistic action between TNF-α and further inhibitory properties of diclofenac [46].
Reduced cell migration capacity and delayed attachment may be caused by a disrupted
homeostasis of the cytoskeleton due to ibuprofen or diclofenac treatment. Indeed, phalloidin
staining of actin filaments revealed a change in morphology after treatment. After NSAID
treatment, cells spread more and were thus significantly larger in size. Continuous actin poly-
merization at the leading edge is required to stabilize membrane protrusions and enable cell
migration [47]. We hypothesized a treatment induced increase of F-actin which exceeds the
homeostasis between actin states consequently interfering with migration [48]. However, our
data did not reveal significant changes in the F-/G-actin ratio of treated cells. This indicates
that other cytoskeletal components such as the microtubule network may be affected, as those
also contribute to establish and maintain polarity in migrating cells [49,50]. However, these
investigations were beyond the scope of this work.
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In our assays, NSAID treatment induced attachment delay, but increased adherence at the
end of the assays, which was indicated by enhanced spreading. Cell adhesion formation and
maintenance is a very complex and well-regulated process (for detailed reviews see [51,52]).
Hence, at this point, we can only speculate about a possible role of ibuprofen and diclofenac in
one or multiple mechanisms mediating the proper turnover of cell attachment. Future studies
will unravel the impact of ibuprofen and diclofenac treatment on the above mentioned aspects
of adhesion formation, regulation, and it´s integration into different migration steps.
Our data further show that ibuprofen reduces lactate levels, but to a lower extent than diclo-
fenac. The results obtained here on lactate levels following diclofenac treatment are in accor-
dance with earlier data from our group [35], where we showed that diclofenac reduced
extracellular lactate levels and lead to a significant reduction of glioma cell migration. The
decrease of lactate was induced at physiological, non-toxic concentrations of diclofenac. This is
in support of published data from our group, which indicated that reduced lactate levels are
accompanied by a dose-dependent inhibition of cell growth [17,18]. Consequently, it can be
assumed that the effects of ibuprofen on migration and proliferation of glioma cells are less
dependent on lactate modulation, especially at lower dosages.
A substantial modulation of STAT-3 signalling by ibuprofen and diclofenac was assumed as
LDH-A is a direct target of c-myc [37], which itself is induced by STAT-3 [53]. Indeed, both
agents decreased STAT-3 phosphorylation at its physiological active amino acid Y705. STAT-3
is a pivotal transcription factor, phosphorylated by receptor-associated kinases in response to
several stimuli, and thus is a key player in many cellular processes such as cell growth and apo-
ptosis. STAT-3 has been assumed to modulate the transition from an epithelial to a migratory
mesenchymal phenotype in glioblastoma [26] and to promote tumorigenicity of glioma stem-
like cells [54]. Modulation of STAT-3 by ibuprofen or diclofenac may therefore constitute a
mechanism of action that could improve the treatment of high-grade glioma. To further sub-
stantiate the role of STAT-3, we investigated the signalling pattern and functional effects on
proliferation and migration after treatment with STATTIC, a specific inhibitor of STAT-3
phosphorylation. As expected, and similar to the effects of diclofenac and ibuprofen, STATTIC
restricted STAT-3 phosphorylation, leading to cell cytotoxicity at high levels [39] along with a
down-regulation of LDH-A activity [55,56]. This is in line with published data showing anti-
tumor activity of STATTIC and its induction of chemo- and radio-sensitivity [57]. However,
despite its effect on LDH-A expression and activity, ibuprofen led to an increase of c-myc pro-
tein expression.
Ibuprofen may, therefore, exert a c-myc-independent mechanism of LDH-A activity mod-
ulation, which occurs only with the highest concentrations of ibuprofen, and in congruence
with the decrease of lactate levels. This may be due to a reduced cell number or cytotoxicity,
even though data were normalized to cell number and ibuprofen did not influence prolifera-
tion within 24 hours. Ibuprofen may consequently act via inhibition of NF-κB, mediated by
suppression of TNF-induced IκB kinase activity, which prevents IκBα degradation [58]. In
addition, although not directly proven, restriction of STAT-3 phosphorylation could consti-
tute a c-myc- and COX-independent mechanism of the anti-tumorigenic effect of ibuprofen
and diclofenac. Ibuprofen decreased migration as effectively as STATTIC, whereas diclofenac
was less effective, indicating a stronger effect of ibuprofen on STAT-3. However, both
NSAIDs achieved better restriction of proliferation than the STAT-3 specific inhibitor
STATTIC, indicating additional (diclofenac) or alternative (ibuprofen) mechanisms.
In addition to inhibition of LDH expression and activity mediated by STAT-3 and c-myc,
altered lactate efflux may be an alternative mechanism which could account for the observed
reduced lactate levels after treatment with diclofenac and ibuprofen. Lactate is transported
through the plasma membrane by proton-linked monocarboxylate transporters [23]. NSAIDs
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may possess monocarboxylic acid structures and may, therefore, competitively inhibit MCT
function [59–61]. Glioma cells mainly express MCT-1 and MCT-4, but with differences in
their cytosolic or membrane-bound localization [62], hence both agents influence additional
pathways.
New anti-neoplastic candidates derived from drug-repurposing studies often yield their
effects only in concentrations far above those that are regularly reached in humans, which is a
crucial point for translation into clinical trails. Therefore, the significant glioma cell restricting
effects of ibuprofen in high dosages might be expected, but more importantly, also physiologi-
cal dosages were sufficient to inhibit glioma cells, when administered on a long-term basis. To
further improve glioma treatment, a combined therapy with ibuprofen and diclofenac may be
of value. Additionally, localized increases in ibuprofen concentration in regions of interest may
be possible by use of ibuprofen nanocarriers [40].
In conclusion, this study indicates a novel mechanism for the functional effects yielded by
ibuprofen in glioma cell lines in vitro. Our data further suggest the need to evaluate the
response to NSAIDs and their efficacy as an adjuvant therapy in patients with high-grade gli-
oma, especially glioblastoma. NSAIDs are clinically available, reach therapeutic concentrations
in humans, and are well tolerated. Thus, clinical trials could integrate ibuprofen or diclofenac
into a standard therapy regimen with the aim to restrict glioma proliferation and migration.
Further comparative studies should affirm the effects of ibuprofen and diclofenac on glioma
cells in vitro and in vivo as well as elucidate their molecular mechanisms of action in more
detail.
Supporting Information
S1 Fig. Both Ibuprofen and diclofenac decrease proliferation in A172 and U87MG. Corre-
sponding to Fig 2, the proliferation abilities of glioma cell lines A172 and U87MG were ana-
lyzed after ibuprofen (0.5, 1, 2 mM), diclofenac (0.05, 0.1, 0.2 mM), or ASA (0.05, 0.1,
0.2 mM) treatment (A, B). At 96 and 120 h, all ibuprofen concentrations achieved significant
reduction of A172’s and U87MG’s proliferation (compared to non-treated Ctrl, 95% CI,
p< 0.0001). Ibuprofen proved to be more effective in A172 (A). Significant values were as
follows: (A) 48 h: 2 mM = 0.001> p  0.0001, 48 h: 1 mM = 0.05> p  0.01; (B) 48 and
72 h: 2 mM = p < 0.0001, 72 h: 1 mM = 0.001> p 0.0001. (C, D) Similar proliferation
inhibiting effects were obtained with diclofenac. At 96 and 120 h, all concentrations resulted
in a significant reduction (compared to DMSO Ctrl, 95% CI, p< 0.0001). However, diclofenac
was not as effective as ibuprofen on A172 cells (compare Figs A and C). Significant values were:
(C) 48 and 72 h: 2 mM = p< 0.0001, 72 h: 1 mM = p< 0.0001; (D) 48 h: 0.2 mM = 0.01> p
0.001, 72 h: 2 mM = p< 0.0001. (E) ASA had time-dependent effects in A172 with the highest
concentration of 0.2 mM (72, 96 and 120 h: 0.2 mM = 0.001> p 0.0001), but was not as effec-
tive as diclofenac or ibuprofen. (F) ASA has neither concentration- nor time-dependent effects on
U87MG cell proliferation as all ASA concentrations significantly decrease proliferation only at
120 h (significant value: 96 h: 2 mM = 0.01> p 0.001).
(TIF)
S2 Fig. Ibuprofen and diclofenac induce cell cycle arrest in HTZ-349 A172 and U87MG.
Ibuprofen and diclofenac induced cell cycle arrest in all cell lines, although at different check-
points. The most prominent effects were observed from diclofenac treatment in HTZ-349,
where increasing concentrations resulted in a sub-G1 peak, indicating cell death (Figs A and
D). This was not observed in A172 (Fig B) or U87MG (Fig C). Figures depict representative
histograms of each treatment.
(TIF)
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S3 Fig. Ibuprofen reduces migration in HTZ-349, A172 and U87MG. Ibuprofen decreased
migration in a time- and concentration-dependent manner in all glioma lines starting 6 h after
treatment compared to a non-treated control (95% CI,  = p< 0.0001). (A) Bar charts corre-
sponding to the migration curves for HTZ-349 as shown in Fig 4A. (B) Similar response to ibu-
profen was observed for the glioma line A172. (C) Response was increased in U87MG cells as
all concentrations achieved significant inhibition of migration after only 6 h of exposure to ibu-
profen. Statistics:  = 0.05> p 0.01,  = 0.01> p 0.001,  = 0.001> p 0.0001,  =
p< 0.0001.
(TIF)
S4 Fig. Diclofenac reduces migration in HTZ-349, A172, and U87MG. Corresponding to
Fig 4B, a migration decrease after diclofenac treatment was measured in all three glioma lines.
Similar to ibuprofen, diclofenac treatment resulted in migration decrease in a time- and con-
centration-dependent manner. Regulation was significant from 24 h after treatment onset
(compared to DMSO Ctrl (95% CI,  = p< 0.0001) in HTZ-349 and A172, whereas
U87MG showed resistance until 30 h. (A) Bar charts corresponding to the migration curves for
HTZ-349 as shown in Fig 4B. (B) A172 responded to diclofenac to less extent. (C) In contrast
to ibuprofen, U87MG cells showed resistance to all diclofenac concentrations until 30 h of
exposure, when the highest concentrations (0.1 and 0.2 mM) achieved significance (). Statis-
tics:  = 0.05> p 0.01,  = 0.01> p 0.001,  = 0.001> p 0.0001,  = p< 0.0001.
(TIF)
S5 Fig. Western blot quantification to Fig 6A (HTZ-349). For quantification purposes, we
evaluated the Western blot from Fig 6A and two additional blots. (A) Expression of c-myc was
significantly increased in a concentration-dependent manner after ibuprofen treatment. Addi-
tionally, a trend towards reduced pSTAT-3 expression was observed. (B) Likewise, distinct
effects were obtained with diclofenac, as pSTAT-3 was reduced in a concentration-dependent
way. In contrast to ibuprofen, diclofenac reduced c-myc expression significantly (0.2 mM),
and LDH-A had a tendency towards decreased expression. Statistics: 90% CI,  = 0.1>
p 0.01,  = 0.01> p 0.001,  = p< 0.0001.
(TIF)
S6 Fig. Ibuprofen and diclofenac have different effects on STAT-3 signalling in A172.
Protein expression in A172 cells was analyzed after incubation with increasing ibuprofen (0.5,
1, 2 mM) or diclofenac concentrations (0.05, 0.1, 0.2 mM) for 24 h. (A, B) Depending on con-
centration, ibuprofen and diclofenac reduced STAT-3 phosphorylation significantly without
affecting total STAT-3 levels. C-myc was significantly down regulated by diclofenac, whereas
ibuprofen had a tendency to increase protein expression. LDH-A was reduced, but not to sig-
nificant extent. Statistics:  = 0.05> p 0.01,  = 0.01> p 0.001,  = 0.001> p 0.0001,
 = p< 0.0001. (C) Corresponding quantitative RT-PCR revealed a significant LDH-A tran-
script decrease only with ibuprofen (2 mM, compared to DMSO Ctrl, 95% CI,  =
0.05> p 0.01). A trend towards LDH-A expression decrease was observed with diclofenac
(0.2 mM), whereas ASA (0.2 mM) had no effect.
(TIF)
S7 Fig. Ibuprofen and diclofenac have different effects on STAT-3 signalling in U87MG.
Protein expression in U87MG cells was analyzed after incubation with increasing ibuprofen
(0.5, 1, 2 mM) or diclofenac concentrations (0.05, 0.1, 0.2 mM) for 24 h. (A, B) Depending on
concentration, ibuprofen and diclofenac reduced STAT-3 phosphorylation significantly with-
out affecting total STAT-3 levels. Expression of c-myc was not affected by diclofenac, whereas
ibuprofen caused significant expression increase. A significant decrease, in a concentration-
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dependent manner, was observed for LDH-A when exposed to diclofenac, while ibuprofen
did not affect protein amounts. Statistics: 95% CI,  = 0.05> p 0.01,  = 0.01> p 0.001,
 = 0.001> p 0.0001,  = p< 0.0001. (C) Corresponding quantitative RT-PCR revealed
a significant LDH-A transcript decrease only with diclofenac (0.2 mM, compared to DMSO
Ctrl, 95% CI,  = 0.05> p 0.01), while ibuprofen and ASA (0.2 mM) had no effect.
(TIF)
S8 Fig. Western blot quantification corresponding to Fig 7A (HTZ-349) and mRNA
expression of LDH-A after exposure to STATTIC. (A) For quantification purposes, two
more blots were evaluated in addition to the exemplary Western blot from Fig 7A. In line with
a decrease of STAT-3 phosphorylation at Y705, expression of c-myc was significantly reduced
in a concentration-dependent manner after STATTIC treatment. Total STAT-3 expression
was not altered. STATTIC proved to be specific as phosphorylation at S727 of STAT-3 was not
significantly affected. Statistics: 95% CI,  = 0.05> p 0.01,  = 0.01> p 0.001,  =
p< 0.0001. LDH-A protein expression was not decreased within 24 h of exposure to STAT-
TIC. (B) However, on mRNA levels, LDH-A was significantly decreased compared to DMSO
control. (C) Percentage decrease of migration was reduced at every time point. A small
decrease was observed after 6 h and a strong reduction at 24 and 30 h compared to DMSO Ctrl.
Statistics: 95% CI,  = 0.05> p 0.01,  = 0.001> p 0.0001.
(TIF)
S9 Fig. Inhibition of STAT-3 phosphorylation changes signalling patterns along with func-
tional effects in A172. (A) Phosphorylated STAT-3 (Y705) and c-myc were decreased specifi-
cally and concentration-dependent in A172 exposed to STATTIC (compared to DMSO Ctrl,
95% CI, 10 μM:  = 0.001> p 0.0001, 20 μM:  = p< 0.0001). Concurrently, total
STAT-3 and STAT-3 phosphorylated at S727 remained at the same level. Additionally, LDH-A
remained unchanged as well. (B) All STATTIC concentrations indicated a significant decrease
of cell migration beginning at 24 h after treatment (95% CI,  = p< 0.0001). (C) Accord-
ingly, proliferation was decreased, with a significant decline at 20 μM (95% CI,  =
p< 0.0001).
(TIF)
S10 Fig. Inhibition of STAT-3 phosphorylation altered signalling patterns along with func-
tional effects in U87MG. (A) In U87MG exposed to STATTIC, phosphorylated STAT-3
(Y705) was decreased specifically in a concentration-dependent manner (compared to DMSO
Ctrl, 95% CI, 5 μM:  = 0.05> p 0.01, 10 μM:  = 0.001> p 0.0001, 20 μM:  =
p< 0.0001). Corresponding effects were observed for LDH-A (20 μM:  = 0.05> p 0.01).
Total STAT-3 and STAT-3 phosphorylated at S727 remained at the same level. Additionally,
c-myc was decreased with 20 μM STATTIC ( = 0.05> p 0.01). (B) 24 h after treatment,
all STATTIC concentrations achieved a significant restriction of cell migration (95% CI,  =
p< 0.0001; 6 h: 15 μM =  = 0.001> p 0.0001). (C) Accordingly, proliferation was
decreased, with a significant decline at 96 h with 10 and 20 μM (95% CI,  = p< 0.0001).
48 h after treatment, 20 μM of STATTIC achieved a significant decrease ( = 0.05> p 0.01).
(TIF)
S1 File. Supplementary Materials and Methods. Actin staining and G-/F-actin measurement.
(DOCX)
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